Tag:
Alexion Pharmaceuticals
Latest Headlines
Latest Headlines
How do the 12 priciest drugs in the U.S. stack up?
Last week, Vertex Pharmaceuticals ( $VRTX ) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as
UPDATED: Alexion scoops up rare disease drug in $1.08B Enobia buyout
Alexion Pharmaceuticals ( $ALXN ) didn't let last week's holiday break slow down its game plan for beefing up its pipeline. The developer announced a $1.08 billion deal to buy Enobia . The Canadian
Booming Alexion blueprints new space for fast-growing staff
Fast-growing Alexion Pharmaceuticals is hiring. After snagging Taligen Therapeutics near the beginning of this year for $111 million plus a milestone package, the biotech says that it now plans to
Investors scour biotechs in search of the next big payoff
With investors cashing in on Genzyme's buyout investors are scouring the biotech landscape for new developers to back in hopes of making similar returns. Dow Jones polled a list of analysts, and some
Which specialty drugmakers should Big Pharma buy?
Every so often, someone sets up a dartboard of likely targets for Big Pharma buyouts. This time, the target-setter is Barron's, and the focus is on companies with market values of $10 billion or
Alexion snaps up Taligen for $111M-plus, creates translational unit
The promising protein drug developer Taligen Therapeutics is being snapped up by Alexion Pharmaceuticals for $111 million upfront and an undisclosed package of milestones for six of its drug
Novartis challenges Soliris patent in EU
Alexion Pharmaceuticals says in a filing that Novartis has filed an opposition to its European patent on Soliris (eculizumab), a treatment for paroxysmal nocturnal hemoglobinuria, a rare blood
R&D success puts Alexion at the top of the M&A list
There's nothing like a successful development record when it comes to attracting attention as a potential M&A target. For Alexion, you can also add new research for Soliris, the world's most
Which drugs get the most-expensive crown?
If you wonder why Big Pharma is so interested in drugs for rare diseases, here's a possibility: High prices. In fact, a new Forbes survey finds that the cost of meds targeted to small groups of
Analyst picks reform bill's biggest biotech winners
Rockefeller & Co analyst David Song sees a lot of healthcare companies coming out ahead in the event the new healthcare reform bill passes Congress. In particular, he cites Amgen and Alexion as
